The new oral small-molecule diabetes drug LX4211 is waiting for FDA review to start stage I clinical trials.
According to Lexicon Executive Vice President and Chief Scientific Officer Brian Zambrowicz, LX4211 specifically blocks reabsorption of glucose by the kidney, which may help to improve glucose control in patients with type 2 diabetes.
Type 1 Diabetes is associated with deficiency (or lack) of insulin. It is not known why, but the pancreatic islet cells quit producing insulin in the quantities needed to maintain a normal blood glucose level. Without sufficient insulin, the blood glucose rises to levels which can cause some of the common symptoms of hyperglycemia.
Type 2 Diabetes is associated with insulin resistance rather than the lack of insulin like seen in Type 1 Diabetes. Insulin levels in these patients are usually normal or higher than average but the body’s cells are rather sluggish to respond to it. This lack of insulin activity results in higher than normal blood glucose levels.
Filed under Diabetes, Diabetes Drug | Tags: biopharmaceutical company, hyperglycemia, Insulin, Lexicon Pharmaceuticals Inc., new Type 2 diabetes drug LX4211, type 1 diabetes, type 2 diabetes, U.S. Food and Drug Administration | Comment Below